Floatz Rating
B62/100
Confidence
Indicative
Sponsor
Prof Gordon Jayson
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
60High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07648745CT.gov Does Cediranib Prevent Bowel Perforation in Platinum-resistant Ovarian Cancer | — | Completed | — | — | — |
NCT02627443CT.gov Carboplatin, Gemcitabine Hydrochloride, and Berzosertib in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | — | Active Not Recruiting | — | — | — |
NCT02726997CT.gov Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer (N-Dur) | — | Active Not Recruiting | — | — | — |
NCT02520154CT.gov Pembrolizumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | — | Completed | — | — | — |
NCT02142803CT.gov TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT01982487CT.gov Vaccine Therapy and IDO1 Inhibitor INCB024360 in Treating Patients With Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Are in Remission | — | Withdrawn | — | — | — |
NCT02046421CT.gov Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | — | Completed | — | — | — |
NCT01749397CT.gov Veliparib and Floxuridine in Treating Patients With Metastatic Epithelial Ovarian, Primary Peritoneal Cavity, or Fallopian Tube Cancer | — | Completed | — | — | — |
NCT01402271CT.gov Pazopanib Hydrochloride, Paclitaxel, and Carboplatin in Treating Patients With Refractory or Resistant Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer | — | Completed | — | — | — |
NCT01065662CT.gov AZD2171 and Temsirolimus in Patients With Advanced Gynecological Malignancies | — | Completed | — | — | — |
Show 5 more trialsShow fewer
NCT00522301CT.gov Sorafenib in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in at Least the Second Remission | — | Terminated | — | — | — |
NCT00436501CT.gov VEGF Trap and Docetaxel in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | — | Completed | — | — | — |
NCT00278343CT.gov Cediranib Maleate in Treating Patients With Persistent, Recurrent, or Refractory Advanced Ovarian Epithelial, Peritoneal Cavity, or Fallopian Tube Cancer | — | Completed | — | — | — |
NCT00275028CT.gov AZD2171 in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer | — | Completed | — | — | — |
NCT00087191CT.gov EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Fallopian Tube Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Cediranib (this asset) | Prof Gordon Jayson | P2 | B · 62 |
| Mirvetuximab Soravtansine | AbbVie | P3 | BB |
| Adriamycin | Sichuan Baili Pharmaceutical Co., Ltd. | P3 | BB |
| Carboplatin | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | P3 | BB |
| Irinotecan | Tianjin Medical University Cancer Institute and Hospital | P3 | BB |
| Cis-Diamminedichloroplatinum Ii | GOG Foundation | P3 | BB |
| Nogitecan | Sichuan Baili Pharmaceutical Co., Ltd. | P3 | BB |
| Cyclophosphamide | Second Affiliated Hospital, School of Medicine, Zhejiang University | P3 | BB |
| Glutathione | Alliance for Clinical Trials in Oncology | P3 | BB |
+42 more in the Fallopian Tube Cancer cohort
Other indications for Cediranib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Gliosarcoma | — | P2 | BBB · 76 |
| Adult Glioblastoma | — | P2 | BBB · 73 |
| Metastatic Melanoma | — | P2 | BBB · 73 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Cediranib in Fallopian Tube Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cediranib-fallopian-tube-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →